A retrospective, single center study of 9 years' experience of drug reactions occurring after the application of parenteral medications to children with rheumatic diseases by a CNS
Latest Information Update: 29 Apr 2021
Price :
$35 *
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Anakinra (Primary) ; Canakinumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Methotrexate (Primary) ; Methylprednisolone (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 29 Apr 2021 New trial record